GFM
IMVT icon

GF Fund Management’s Immunovant IMVT Stock Holding History

GF Fund Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
4,308
+372
+9% +$11.3K ﹤0.01% 290
2026
Q1 		$97.8K Buy
3,936
+493
+14% +$12.8K ﹤0.01% 344
2025
Q4 		$87.5K Sell
3,443
-307
-8% -$6.85K ﹤0.01% 357
2025
Q3 		$60.5K Sell
3,750
-8
-0.2% -$130 ﹤0.01% 376
2025
Q2 		$60.1K Hold
3,758
– – ﹤0.01% 401
2025
Q1 		$64.2K Buy
3,758
+676
+22% +$14.1K ﹤0.01% 398
2024
Q4 		$76.3K Buy
+3,082
New +$87.4K ﹤0.01% 351

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GF Fund Management's IMVT Position: Q2 2026 in Review

GF Fund Management increased its Immunovant (IMVT) stake by 9.5% in Q2 2026, buying an estimated $11.3K and bringing the position to 4,308 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #290.

GF Fund Management first reported a position in IMVT in Q4 2024 and has held it in 7 quarters since. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • GF Fund Management held 4,308 shares of Immunovant worth $166K as of Q2 2026.
  • GF Fund Management bought 372 Immunovant shares in Q2 2026, an estimated $11.3K.
  • Immunovant made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #290 holding.
  • GF Fund Management first reported a position in Immunovant in Q4 2024 and has held it in 7 quarters since.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.